Introduction
A mutation in the precore region of hepatitis B virus (HBV) DNA is closely related to seroconversion of hepatitis B e antigen (HBeAg) in carriers of HBV 1, 2) . Furthermore, the relationship between a mutation in the precore region of HBV DNA and a fulminant change has attracted a great deal of attention in patients with acute hepatitis due to HBV3)-5). However, there have been few reports about the relationship between the mutation in the precore region of HBV DNA and other clinical forms, such as in patients with severe acute hepatitis, with the complicated form or with multiple transaminase peaks.
We treated 10 patients who suffered from acute hepatitis due to HBV which had various clinical forms including fulminant hepatitis that differed from those of typical cases. We studied HBV markers in their sera and analyzed the precore region of HBV DNA in those patients.
Subjects and Methods

Subjects
We chose 10 patients with atypical course from patients with acute hepatitis due to HBV who had been admitted to Jikei University Kashiwa Hospital (Table 1) . The patients included nine men and one woman ranging in age from 21 to 66 years. All patients had a serum alanine aminotransferase (ALT) level of more than 1600 mU/ml. Two patients had fulminant hepatitis. An additional patient with the fulminant form of acute HBV infection had chronic liver damage due to alcohol . In these three patients prothrombin activity had decreased to less than 40% and hepatic encephalopathy which was greater than grade II had developed within 8 weeks from the onset of hepatic symptoms . Two of these patients died of hepatic failure. In the five patients who had severe acute hepatitis , the results of the hepaplastin test were less than 40% . One patient was complicated by myopathy , and another patient had an atypical clinical course in which serum levels of transaminase peaked three times . Assay for markers of hepatitis viruses The presence of hepatitis B surface antigen (HBsAg) and the antibody against HBs (anti -H Bs) was determined by radioimmunoassay (RIA) or enzyme immunoassay , and HBeAg, the antibody against HBe (anti-HBe), and the IgM antibody to hepatitis B core antigen (IgM anti -HBc) were determined by RIA. The values of HBsAg , HBeAg and IgM anti-HBc were indicated as cut-off indeices, and that of and-HBe as percent inhibition . DNA polymerase was assayed by means of incorportation of radioactive thymidine into DNA , and its value was indicated by cpm6). The IgM antibody to hepatitis A virus (IgM anti-HA) was determined by RIA , and the antibody to hepatitis C virus (anti-HCV) was assayed with a second-generation HCV enzyme immunoassay kit (Dainabot Co ., Ltd., Tokyo). HCV RNA was detected with a two-stage polymerase chain reaction (PCR) with two pairs of primers from the 5'-noncoding region7). Analysis of the precore region of HBV DNA by PCR A mutant virus with a point mutation that changes codon 28 (TGG) of the precore region to a stop codon (TAG) was detectd by restriction fragment length polymorphism (RFLP) . A primer at the 5' end was designed as a mismatch primer between nucleotide positions 1875 and 1895 (5' AAGCTGTGC -CTTGGGTGGCCTT3') to amplify the HBV DNA sensitive to digestion with Bsu36 I in mutant virus (Smi Test, Institute of Immunology, Co., Ltd., Tokyor.
Results
Results of HBV markers including analysis of the precore region HBsAg was positive in all except one of the patients and IgM anti -HBc was positive in all 10 . On the basis of the presence of HBeAg and anti-HBe , patients were divided into three groups on admission. In five patients HBeAg was positive and anti-HBe was negative . In three patients both HBeAg and anti-HBe were positive and in two patients HBeAg was negative and anti-HBe was positive ( Table 2) . Bands digested by Bsu36 I were detected by RFLP ( Fig. 1) : the mutant pattern was detected in patients with fulminant hepatitis (cases 1 and 2) and in a patient with the most severe acute hepatitis (case 4). Bands after digestion by Sty I, indicating a wild-type pattern, were detected in the other cases (Table 2) . A mixed pattern of mutant and wild-type viruses was not observed. Clinical course and HBV markers in three cases The patient in case 1 was a 21-year-old woman. She had fulminant hepatitis complicated by acute renal failure. The serum level of ALT had increased to 8870 mU/ml, prothrombin time had decreased to 12%, and hepatic encephalopathy was grade III. She recovered with intensive treatment, such as plasma exchange and interferon therapy. At the time of admission HBsAg (8.2), IgM anti-HBc (9.0), and HBeAg (2.0) were positive, and DNA polymerase (16) and anti-HBe (17) were negative. Analysis of the precore region of HBV DNA by RFLP revealed a mutant pattern, and the detected bands pre-C (RFLP) Mutant disappeared soon after interferon treatment started . IgM anti-HA, anti-HCV, and HCV-RNA were negative ( Figs. 1 and 2 ). In case 9 the patient was a 58-year-old man . From the onset of hepatitis this case was complicated by myopathy with myalgia and muscle weakness . By electromyography, low-amplitude waves were observed, mainly in the upper extremities . In the acute stage of hepatitis, HBsAg (42) , IgM anti-HBc (7.5), and HBeAg (83) were positive, and anti-HBe was negative (0) . Analysis of the precore region of HBV DNA by RFLP revealed a wild-type pattern (Fig . 3) . Fig. 3 Clinical courses of a patient with acute hepatitis complicated by myopathy (case 9) and a patient with acute hepatitis having three transaminase peaks (case 10). Analysis of the precore (pre-C) region of HBV DNA by RFLP revealed a wild-type pattern in both patients. ALT, alanine aminotransferase; T. Bil , total bilirubin; C.I., cut-off index.
Case 9 Case 10
The patient in case 10 was a 47-year-old man. The clinical course was atypical in that the serum level of transaminase peaked three times (1395, 1364, and 1612 mU/ml) in more than 4 weeks. During the first transaminase peak, HBsAg (59), IgM anti-HBc (6.5), HBeAg (47), and DNA polymerase (153) were positive, and anti-HBe was negative (0). During the third transaminase peak HBeAg was still 
